R&D Spending Showdown: United Therapeutics Corporation vs ACADIA Pharmaceuticals Inc.

Pharma Giants' R&D Spending: A Decade of Innovation

__timestampACADIA Pharmaceuticals Inc.United Therapeutics Corporation
Wednesday, January 1, 201460602000242549000
Thursday, January 1, 201573869000245098000
Friday, January 1, 201699284000147600000
Sunday, January 1, 2017149189000264600000
Monday, January 1, 2018187163000357900000
Tuesday, January 1, 20192403850001182600000
Wednesday, January 1, 2020319130000357700000
Friday, January 1, 2021239415000540100000
Saturday, January 1, 2022361575000322900000
Sunday, January 1, 2023351619000408000000
Loading chart...

Unlocking the unknown

R&D Spending Trends: A Decade of Innovation

In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, United Therapeutics Corporation and ACADIA Pharmaceuticals Inc. have demonstrated contrasting strategies in their R&D investments.

From 2014 to 2023, United Therapeutics consistently outpaced ACADIA in R&D spending, peaking in 2019 with a staggering 1.18 billion dollars, nearly four times ACADIA's expenditure that year. However, ACADIA has shown a remarkable growth trajectory, increasing its R&D budget by over 480% from 2014 to 2023.

In 2023, United Therapeutics spent approximately 16% more on R&D than ACADIA, highlighting its sustained focus on innovation. These trends underscore the dynamic nature of the pharmaceutical industry, where strategic R&D investments can drive future breakthroughs and market leadership.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025